Health
The FDA now says Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss
By Katherine Langford
Peloton Draws $6.8 Billion Demand for Debut Junk-Bond Sale
Marcus Chen
Marcus Chen
Managing Editor · St. Paul, MN
Marcus manages the day-to-day editorial workflow across all brands, coordinating coverage assignments and ensuring editorial standards are met. He previously served as city editor at the Pioneer Press and holds a degree in Political Science from Carleton College.
More from Marcus →Managing Editor · Tuesday, November 10, 2026 at 5:02 PM · 1 min read
Peloton Interactive Inc. has attracted strong investor demand for its debut junk-bond sale, allowing the fitness company to boost the deal’s size and slash borrowing costs.
Up nextThe FDA now says Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision lossHealth · 1 min read
